Stryker
Market Cap
US$81.3b
Last Updated
2020/01/22 23:48 UTC
Data Sources
Company Financials +
Executive Summary
Stryker Corporation operates as a medical technology company.
Rewards
Risk Analysis
Snowflake Analysis
Solid track record average dividend payer.
Similar Companies
Share Price & News
How has Stryker's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SYK has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
5.0%
SYK
2.3%
US Medical Equipment
0.6%
US Market
1 Year Return
30.9%
SYK
30.3%
US Medical Equipment
24.6%
US Market
Return vs Industry: SYK exceeded the US Medical Equipment industry which returned 27.5% over the past year.
Return vs Market: SYK exceeded the US Market which returned 23.2% over the past year.
Shareholder returns
| SYK | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.0% | 2.3% | 0.6% |
| 30 Day | 2.1% | 4.3% | 3.0% |
| 90 Day | 2.7% | 13.8% | 10.6% |
| 1 Year | 32.3%30.9% | 31.3%30.3% | 27.3%24.6% |
| 3 Year | 85.5%79.2% | 96.4%90.7% | 50.5%40.8% |
| 5 Year | 149.3%134.0% | 133.4%108.5% | 78.9%59.1% |
Price Volatility Vs. Market
How volatile is Stryker's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Should You Like Stryker Corporation’s (NYSE:SYK) High Return On Capital Employed?2 weeks ago | Simply Wall St
Should You Be Worried About Insider Transactions At Stryker Corporation (NYSE:SYK)?1 month ago | Simply Wall St
Do Insiders Own Lots Of Shares In Stryker Corporation (NYSE:SYK)?Valuation
Is Stryker undervalued compared to its fair value and its price relative to the market?
3.2%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SYK ($207.96) is trading below our estimate of fair value ($223.8)
Significantly Below Fair Value: SYK is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: SYK is good value based on its PE Ratio (22.7x) compared to the Medical Equipment industry average (46.3x).
PE vs Market: SYK is poor value based on its PE Ratio (22.7x) compared to the US market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: SYK is poor value based on its PEG Ratio (2.2x)
Price to Book Ratio
PB vs Industry: SYK is overvalued based on its PB Ratio (6.3x) compared to the US Medical Equipment industry average (4.1x).
Next Steps
Future Growth
How is Stryker forecast to perform in the next 1 to 3 years based on estimates from 26 analysts?
10.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SYK's forecast earnings growth (10.3% per year) is above the savings rate (1.7%).
Earnings vs Market: SYK's earnings (10.3% per year) are forecast to grow slower than the US market (14.3% per year).
High Growth Earnings: SYK's earnings are forecast to grow, but not significantly.
Revenue vs Market: SYK's revenue (6.2% per year) is forecast to grow slower than the US market (7.5% per year).
High Growth Revenue: SYK's revenue (6.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SYK's Return on Equity is forecast to be low in 3 years time (19.9%).
Next Steps
Past Performance
How has Stryker performed over the past 5 years?
28.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SYK has a large one-off loss of $929.0M impacting its September 30 2019 financial results.
Growing Profit Margin: SYK's current net profit margins (23.5%) are higher than last year (9.3%).
Past Earnings Growth Analysis
Earnings Trend: SYK's earnings have grown significantly by 28% per year over the past 5 years.
Accelerating Growth: SYK's earnings growth over the past year (177.2%) exceeds its 5-year average (28% per year).
Earnings vs Industry: SYK earnings growth over the past year (177.2%) exceeded the Medical Equipment industry 31%.
Return on Equity
High ROE: SYK's Return on Equity (27.8%) is considered high.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Stryker's financial position?
Financial Position Analysis
Short Term Liabilities: SYK's short term assets ($8.6B) exceed its short term liabilities ($3.9B).
Long Term Liabilities: SYK's short term assets ($8.6B) do not cover its long term liabilities ($10.4B).
Debt to Equity History and Analysis
Debt Level: SYK's debt to equity ratio (68.3%) is considered high.
Reducing Debt: SYK's debt to equity ratio has increased from 45.9% to 68.3% over the past 5 years.
Debt Coverage: SYK's debt is well covered by operating cash flow (29.7%).
Interest Coverage: SYK's interest payments on its debt are well covered by EBIT (29.5x coverage).
Balance Sheet
Inventory Level: SYK has a high level of physical assets or inventory.
Debt Coverage by Assets: SYK's debt is covered by short term assets (assets are 1x debt).
Next Steps
Dividend
What is Stryker's current dividend yield, its reliability and sustainability?
1.06%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: SYK's dividend (1.11%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.4%).
High Dividend: SYK's dividend (1.11%) is low compared to the top 25% of dividend payers in the US market (3.66%).
Stability and Growth of Payments
Stable Dividend: SYK's dividends per share have been stable in the past 10 years.
Growing Dividend: SYK's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (22.7%), SYK's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: SYK's dividends in 3 years are forecast to be well covered by earnings (24.9% payout ratio).
Next Steps
Management
What is the CEO of Stryker's salary, the management and board of directors tenure and is there insider trading?
2.9yrs
Average management tenure
CEO
Kevin Lobo (54yo)
7.3yrs
Tenure
US$13,911,065
Compensation
Mr. Kevin A. Lobo, ACFE has been the Chief Executive Officer of Stryker Corporation since October 1, 2012. Mr. Lobo served as the President of Stryker from October 1, 2012 to August 1, 2018. He served as t ...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD13.91M) is about average for companies of similar size in the US market ($USD10.76M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
Management Age and Tenure
2.9yrs
Average Tenure
53yo
Average Age
Experienced Management: SYK's management team is considered experienced (2.9 years average tenure).
Board Age and Tenure
6.2yrs
Average Tenure
63.5yo
Average Age
Experienced Board: SYK's board of directors are considered experienced (6.2 years average tenure).
Insider Trading
Insider Buying: SYK insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 40 |
| Max Price | US$216.77 |
| Entity | Individual |
| Role | Chief Accounting Officer Principal Accounting Officer |
| Shares | 500 |
| Max Price | US$223.20 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 350 |
| Max Price | US$215.00 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 39,818 |
| Max Price | US$211.57 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 41 |
| Max Price | US$212.84 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 90,182 |
| Max Price | US$214.06 |
| Entity | Individual |
| Shares | 2,000 |
| Max Price | US$190.43 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 43 |
| Max Price | US$188.77 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 2,679 |
| Max Price | US$187.25 |
| Entity | Individual |
| Shares | 180 |
| Max Price | US$176.77 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 46 |
| Max Price | US$177.26 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Tim Scannell (54yo)
President & COO
- Tenure: 1.4yrs
- Compensation: US$6.63m
Bronwen Taylor
Vice President of Compliance & Risk Management
- Tenure: 6.4yrs
Katherine Owen (48yo)
Vice President of Strategy & Investor Relations
- Tenure: 2.9yrs
Robert Cohen
CTO and VP of Global R&D - Joint Replacement
Kevin Lobo (54yo)
Chairman & CEO
- Tenure: 7.3yrs
- Compensation: US$13.91m
William Berry (53yo)
Principal Accounting Officer
- Tenure: 5.9yrs
Mike Hutchinson (48yo)
Advisor to Chief Executive Officer
- Tenure: 0.8yrs
- Compensation: US$2.34m
Glenn Boehnlein (57yo)
VP & CFO
- Tenure: 3.8yrs
- Compensation: US$3.79m
Viju Menon (51yo)
Group President of Global Quality & Operations
- Tenure: 1.8yrs
- Compensation: US$4.39m
Robert Fletcher
VP & Chief Legal Officer
- Tenure: 0.8yrs
Board Members
John Brown (84yo)
Chairman Emeritus
- Compensation: US$286.99k
Ronda Stryker (64yo)
Independent Director
- Tenure: 36yrs
- Compensation: US$290.12k
Mary Brainerd (65yo)
Independent Director
- Tenure: 2.4yrs
- Compensation: US$290.12k
Frederic Doliveux (63yo)
Independent Director
- Tenure: 9.6yrs
- Compensation: US$305.12k
Louise Francesconi (66yo)
Independent Director
- Tenure: 13.5yrs
- Compensation: US$305.12k
Srikant T. Datar (66yo)
Independent Director
- Tenure: 10.5yrs
- Compensation: US$290.12k
Allan Golston (52yo)
Lead Independent Director
- Tenure: 3.3yrs
- Compensation: US$325.12k
Rajeev Suri (52yo)
Independent Director
- Tenure: 1.7yrs
- Compensation: US$251.58k
Andy Silvernail (48yo)
Independent Director
- Tenure: 6.2yrs
- Compensation: US$310.12k
Kevin Lobo (54yo)
Chairman & CEO
- Tenure: 7.3yrs
- Compensation: US$13.91m
Company Information
Stryker Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Stryker Corporation
- Ticker: SYK
- Exchange: NYSE
- Founded: 1941
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$81.271b
- Shares outstanding: 374.40m
- Website: https://www.stryker.com
Number of Employees
Location
- Stryker Corporation
- 2825 Airview Boulevard
- Kalamazoo
- Michigan
- 49002
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SYK | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jan 1980 |
| SYK | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 1980 |
| SYK | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Jan 1980 |
| SYK | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Jan 1980 |
| 0R2S | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jan 1980 |
| SYK * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jan 1980 |
| SYK | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jan 1980 |
Biography
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 80 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.Â
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/22 23:48 |
| End of Day Share Price | 2020/01/22 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.